Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weifuchun vs bismuth quadruple vs standard triple therapy for first-line Helicobacter pylori eradication
ChiCTR-IIR-16008279Phase 4Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- Apr 2016
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of weifuchun, bismuth subcitrate, esomeprazole, amoxicillin and clarithromycin in Helicobacter pylori infection (3 arms), sponsored by Renji Hospital. Primary endpoint: Eradication rate of Helicobacter pylori. Planned start Apr 2016; status: not yet recruiting.
02
Drugs
weifuchunbismuth subcitrateesomeprazoleamoxicillinclarithromycin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR-IIR-16008279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-16008279.